How this supports a project
Modified-peptide planning starts with the exact sequence and modification site, then aligns stereochemistry, protected building blocks, solid-phase or solution installation, cleavage conditions, purification, and site-specific analytical confirmation.
Specify the modified peptide, not only the motif
Lipidation, glycosylation, PEGylation, cyclization, stapling, and reporter installation require an exact residue or terminus, attachment chemistry, stereochemistry, and protected form. The same modification at a different site can change synthesis, purification, conformation, solubility, and biological behavior.
Installation can occur through a premodified amino-acid building block, on-resin functionalization, solution-phase conjugation, chemical ligation, or an enzymatic route. The choice depends on sequence length, side-chain functionality, modification stability, hydrophobicity, aggregation, and compatibility with global cleavage and deprotection.
Typical modified-peptide workflow
Define the complete construct
Provide sequence, termini, stereochemistry, disulfides or cyclization, every noncanonical residue, and each modification site.
Choose an installation route
Select a premodified monomer, orthogonally protected residue, on-resin step, post-cleavage conjugation, ligation, or enzyme-mediated route.
Set protecting-group compatibility
Check side-chain protections, temporary orthogonal groups, coupling reagents, base exposure, acid cleavage, oxidation or reduction, and modification stability.
Plan synthesis and difficult segments
Identify aggregation-prone or hydrophobic regions, glycosylated or lipidated residues, cyclization points, ligation junctions, and any pseudoproline or backbone-protection needs.
Plan purification and material handling
Account for amphiphilicity, closely related deletion or epimerization products, glycoform or lipid heterogeneity, solubility, counterion, and storage.
Confirm the final peptide
Measure identity, purity, mass, modification site, stereochemical or glycoform attributes where required, disulfide or ring closure, aggregation, and retained project-specific function.
Inputs for platform review
Sequence and topology
Full sequence, N- and C-terminal forms, stereochemistry, disulfides, linear or cyclic format, and any ligation junction.
Modification map
Exact residue or terminus for every lipid, glycan, PEG, staple, cross-link, isotope, dye, biotin, click handle, or noncanonical amino acid.
Chemical form
Lipid or glycan identity, linker and attachment bond, protecting state, salt or counterion, and acceptable related forms.
Process constraints
Preferred synthesis route, prohibited reagents or conditions, oxidation sensitivity, solubility limits, scale, purification method, and material form.
Analytical and functional tests
Identity, purity, mass, site confirmation, stereochemistry, glycan or lipid confirmation, ring or disulfide state, solubility, and any binding or activity assay.
Where this platform applies
This platform covers protected amino-acid building blocks, lipidation and PEGylation handles, glycosylated residues, cyclization or stapling inputs, and conjugation-ready peptide intermediates. It does not claim that a modification improves potency, permeability, stability, half-life, selectivity, efficacy, or safety. Such effects are sequence-, site-, format-, and assay-dependent and require testing of the complete peptide.
Core considerations
- Lipidation and fatty-acid spacers
- Glycosylated amino-acid building blocks
- Stapling, cyclization, and click-ready residues
Related catalog and technical pages
Sources
- 1.Synthesis of proteins by native chemical ligation (Science, 1994)
- 2.Solid-phase synthesis of CD52 glycopeptide and an efficient route to Asn-core pentasaccharide conjugate (Bioorganic & Medicinal Chemistry, 1997)
- 3.Simultaneous lipidation of a characterized peptide mixture by chemoselective ligation (Bioconjugate Chemistry, 2003)
- 4.Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix (Science, 2004)